Adicet Bio, Inc.
ACET evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACET—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACET
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies for autoimmune diseases and cancer, with lead candidate ADI-001 in Phase 1 and Phase 2 studies across multiple indications.
Key risk: Capital needs
BioSniper Score
Based on 6 of 6 signals
Market Cap
$84.8M
Cash Runway
17.7 moLead Asset
ADI-001 (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials · 2 catalysts for Adicet Bio, Inc..
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies for autoimmune diseases and cancer, with lead candidate ADI-001 in Phase 1 and Phase 2 studies across multiple indications.
- Lead product candidate ADI-001 is being evaluated in Phase 1 and Phase 2 studies for autoimmune indications including systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis [sec · filed 2025-10-07].
- The company plans to meet with the FDA in Q1 2026 to inform Phase 2 pivotal trial design, with a study anticipated to commence in Q2 2026 [sec · filed 2025-10-07].
- Cash and equivalents were $36.0M as of 2026-06-30, with a net loss of -$21.4M for the quarter, shareholders' equity of $133.4M, and no long-term debt [sec].
- The company anticipates needing substantial additional capital to fund operations and development, and may seek financing through equity, debt, or collaborations [sec_mda · as of 2026-08-05].
- More than 25 clinical sites globally are open for enrollment for the Phase 1 study of ADI-001 in autoimmune indications [sec · filed 2025-10-07].
What works
- ADI-001 is being studied across a broad range of autoimmune indications, potentially addressing large patient populations [sec · filed 2025-10-07].
- The company has established a global clinical footprint with over 25 sites open for enrollment [sec · filed 2025-10-07].
- Adicet has no debt and a manageable cash burn, with $36.0M in cash as of 2026-06-30 [sec].
What to weigh
- The company has a history of net losses, reporting a -$21.4M net loss for the quarter ended 2026-06-30 [sec].
- Adicet will require substantial additional capital to continue development, with no guarantee of securing financing [sec_mda · as of 2026-08-05].
- All product candidates are in clinical or preclinical stages, with no approved products or revenue from product sales [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Phase 1 enrollment is open for multiple autoimmune indications
“The Phase 1 program is now open for enrollment of patients with systemic sclerosis (SSc), idiopathic inflammatory myopathy, stiff person syndrome, anti-neutrophil cytoplasmic autoantibody associated vasculitis and rheumatoid arthritis (RA).”
SEC filings · October 7, 2025
Company plans FDA meeting in Q1 2026 for Phase 2 pivotal trial design
“The Company plans to request a meeting with the U.S. Food and Drug Administration (FDA) in first quarter of 2026 to inform Phase 2 pivotal trial design with a study anticipated to commence in second quarter of 2026.”
SEC filings · October 7, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · adi-212 — Phase 2 Readout: adi-212 — Topline data from the Phase 2 study of adi-212 is expected, which will inform further development.
- 2027-02-15 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux — Topline results from a Phase 3 study of bendamustine and rituximab are anticipated.
Risks & what to watch (3)›
Key risks
- Capital needs — Adicet will require substantial additional capital to fund operations and development; no assurance of raising funds [sec_mda · as of 2026-08-05].
- Clinical-stage only — All product candidates are in clinical or preclinical stages; no approved products or revenue [sec_mda · as of 2026-08-05].
- Regulatory uncertainty — Phase 2 pivotal trial design depends on FDA feedback; delays or changes could impact timelines [sec · filed 2025-10-07].
What to watch
- FDA meeting in Q1 2026 to discuss Phase 2 pivotal trial design for ADI-001 [sec · filed 2025-10-07].
- Phase 2 pivotal study initiation anticipated in Q2 2026 [sec · filed 2025-10-07].
- Enrollment progress across multiple autoimmune indications in Phase 1 [sec · filed 2025-10-07].
- Future financing events to support ongoing operations [sec_mda · as of 2026-08-05].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Adicet Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adicet Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.7 months
D/E 0.23 · 0% dilution
Lead: Phase 1
4 candidates
2 upcoming, next in ~123d
0 buys · 4 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$41.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 1,182,624 | $8.1M |
| orbimed advisors llc | 1,027,944 | $7.0M |
| vanguard capital management llc | 673,048 | $4.6M |
| franklin resources inc | 626,571 | $4.3M |
| citadel advisors llc | 381,823 | $2.6M |
| adage capital partners gp, l.l.c. | 274,375 | $1.9M |
| prosight management, lp | 250,244 | $1.7M |
| renaissance technologies llc | 232,591 | $1.6M |
| alyeska investment group, l.p. | 203,799 | $1.4M |
| carlyle group inc. | 184,295 | $1.3M |
Showing top 10 of 46 institutional holders of Adicet Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 8.1%
- Days to cover
- 5.9
- Shares short
- 656,546
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACET short interestGovernance
Frequently asked questions
What is the AI investment thesis for Adicet Bio, Inc.?
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies for autoimmune diseases and cancer, with lead candidate ADI-001 in Phase 1 and Phase 2 studies across multiple indications.
What is Adicet Bio, Inc.'s lead drug candidate?
Adicet Bio, Inc.'s most advanced tracked candidate is ADI-001 (Phase 1) for Lupus Nephritis; Lymphoma, Follicular.
What is Adicet Bio, Inc.'s next catalyst?
Adicet Bio, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: adi-212" — expected December 31, 2026.
Who is the CEO of Adicet Bio, Inc.?
Mr. Chen Schor BA, CPA, M.B.A. is the chief executive officer of Adicet Bio, Inc. (ACET).
Where is Adicet Bio, Inc. headquartered?
Adicet Bio, Inc. (ACET) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.